<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460756</url>
  </required_header>
  <id_info>
    <org_study_id>1042-PPD-2003</org_study_id>
    <nct_id>NCT03460756</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression</brief_title>
  <official_title>A Phase 2, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Oral Administration of Ganaxolone in Women With Postpartum Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate safety, tolerability and efficacy of oral administration of
      ganaxolone in women with postpartum depression
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>38 days</time_frame>
    <description>Efficacy of oral administered ganaxolone vs. placebo as assessed by change from baseline in the HAMD17 total score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Events</measure>
    <time_frame>38 days</time_frame>
    <description>Safety and tolerability of oral administered ganaxolone vs. placebo as assessed by the incidence of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Measures</measure>
    <time_frame>17 days</time_frame>
    <description>Safety and tolerability of oral administered ganaxolone vs. placebo as assessed by change from baseline in laboratory measures (biochemistry, hematology and urinalysis) per group and number of individuals with potentially clinically significant abnormal values of laboratory assessments in each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Blood Pressure</measure>
    <time_frame>38 days</time_frame>
    <description>Safety and tolerability of oral administered ganaxolone vs. placebo as assessed by potentially clinically significant change from baseline in blood pressure (mm Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Pulse</measure>
    <time_frame>38 Days</time_frame>
    <description>Safety and tolerability of oral administered ganaxolone vs. placebo as assessed by change from baseline in pulse (Beats per minute)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Temperature</measure>
    <time_frame>38 Days</time_frame>
    <description>Safety and tolerability of oral administered ganaxolone vs. placebo as assessed by change from baseline in temperature (C°)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>38 Days</time_frame>
    <description>Assessment of suicidal ideation or behavior by using the CSSRS scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>10 Days</time_frame>
    <description>Change from baseline in ECG measures (e.g. heart rate, PR interval, QRS complex, QTcF) per group and number of individuals with potentially clinically significant abnormal values of ECG measures in each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stanford Sleepiness Scale (SSS)</measure>
    <time_frame>38 Days</time_frame>
    <description>Safety and tolerability of oral administered ganaxolone vs. placebo as assessed by change from baseline in SSS. This scale is measured from 1-7, with 7 being the highest degree of sleepiness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes assessed by Physical Examination</measure>
    <time_frame>10 days</time_frame>
    <description>Number of individuals with potentially significant physical exam findings per group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postnatal Depression Scale (EPDS)</measure>
    <time_frame>38 days</time_frame>
    <description>Efficacy of oral administered ganaxolone vs. placebo as assessed by EPDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spielberger State-Trait Anxiety Inventory six item version (STA6)</measure>
    <time_frame>38 days</time_frame>
    <description>Efficacy of oral administered ganaxolone vs. placebo as assessed by STA6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement</measure>
    <time_frame>38 days</time_frame>
    <description>Efficacy of oral administered ganaxolone vs. placebo as assessed by CGI-I</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Depression</condition>
  <condition>Depression, Postpartum</condition>
  <condition>Behavioral Symptoms</condition>
  <condition>Mood Disorders</condition>
  <condition>Mental Disorder</condition>
  <condition>Pregnancy Complications</condition>
  <condition>Postpartum Blues</condition>
  <condition>PPD</condition>
  <condition>Postpartum Disorder</condition>
  <arm_group>
    <arm_group_label>Ganaxolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganaxolone</intervention_name>
    <description>Oral</description>
    <arm_group_label>Ganaxolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Experiencing a major depressive episode, which started between the start of the third
             trimester and 4 weeks following delivery. The major depressive episode must be
             diagnosed according to Mini International Neuropsychiatric Interview (MINI) 7.0
             interview

          -  Given birth in the last 6 months

          -  HAMD17 score of ≥ 20 at screening but &lt; 26

          -  Must agree to stop breastfeeding from start of study treatment or must agree to
             temporarily cease giving breast milk to her infant(s)

        Exclusion Criteria:

          -  Current history of any psychotic illness, including major depressive episode with
             psychotic features

          -  History of suicide attempt within the past 3 years

          -  History of bipolar I disorder

          -  History of seizure discorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women with postpartum depression</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaakko Lappalainen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Amerine</last_name>
    <phone>484-801-4676</phone>
    <email>wamerine@marinuspharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaakko Lappalainen, MD</last_name>
    <phone>484 801 4678</phone>
    <email>jlappalainen@marinuspharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <zip>19335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>March 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postpartum Care</keyword>
  <keyword>Postpartum Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Behavioral Symptoms</mesh_term>
    <mesh_term>Puerperal Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

